New pharmacological options in the treatment of Alzheimer's disease

被引：2
|
作者：
Kleinova, L. [1 ,2 ]
Cerman, J. [2 ]
Hlavka, J. [3 ]
Hort, J. [2 ]
机构：
[1] 1 LF UK, Vseobecne Lekarstvi, Prague, Czech Republic
[2] Neurol Klin 2 LF UK, Kognitivni Ctr, V Uvalu 84, Prague 15006, Czech Republic
[3] Univ Southern Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA
来源：
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE | 2022年 / 85卷 / 06期
关键词：
Alzheimer?s disease; phase three testing  of new drugs; β -amyloid; tau protein; neuroinflammatory theory; ric symptoms; neuroprotection; BETA; TRAMIPROSATE; INHIBITION; GUANFACINE; DEMENTIA; TRIAL;
D O I：
10.48095/cccsnn2022462
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
A new era of innovative treatment options for Alzheimer's disease is emerging. New goals of treatment are being developed with various monoclonal antibodies targeting potentially pathological molecules involved in the pathogenesis of Alzheimer's disease. The aim of this review is to acquaint the reader with new potential drugs, while most of those mentioned in this review are in the third phase of clinical trials.
引用
收藏
页码：462 / 469
页数：8
相关论文
共 50 条
  • [31] Molecular rationale for the pharmacological treatment of Alzheimer's disease
    Zimmermann M.
    Gardoni F.
    Di Luca M.
    Drugs & Aging, 2005, 22 (Suppl 1) : 27 - 37
  • [32] New pharmacological treatment options for nonalcoholic fatty liver disease
    Stefan, Norbert
    INTERNIST, 2020, 61 (07): : 759 - 765
  • [33] Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia
    Szeto, Jennifer Y. Y.
    Lewis, Simon J. G.
    CURRENT NEUROPHARMACOLOGY, 2016, 14 (04) : 326 - 338
  • [34] Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent
    Karneboge, Jonas
    Haberstroh, Julia
    Geschke, Katharina
    Perry, Julia
    Radenbach, Katrin
    Jessen, Frank
    Rostamzadeh, Ayda
    ALZHEIMERS & DEMENTIA, 2025, 21 (01)
  • [35] Pharmacological Treatment of Alzheimer Disease
    Massoud, Fadi
    Leger, Gabriel C.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2011, 56 (10): : 579 - 588
  • [36] Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment
    dos Santos Picanco, Leide Caroline
    Ozela, Priscilla F.
    de Brito Brito, Maiara de Fatima
    Pinheiro, Abrado A.
    Padilha, Elias C.
    Braga, Francinaldo S.
    Tomich de Paula da Silva, Carlos Henrique
    Rodrigues dos Santos, Cleydson Breno
    Rosa, Joaquin M. C.
    da Silva Hage-Melim, Lorane Izabel
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (26) : 3141 - 3159
  • [37] New Pharmacological Options for Treating Advanced Parkinson's Disease
    Devos, David
    Moreau, Caroline
    Dujardin, Kathy
    Cabantchik, Ioav
    Defebvre, Luc
    Bordet, Regis
    CLINICAL THERAPEUTICS, 2013, 35 (10) : 1640 - 1652
  • [38] Treatment options in Alzheimer's disease -: What is evidence based?
    Weimer, E
    Frölich, L
    NERVENHEILKUNDE, 2005, 24 (02) : 120 - +
  • [39] The search for better noncholinergic treatment options for Alzheimer's disease
    Mintzer, JE
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 : 18 - 22
  • [40] Alzheimer's disease: Current treatment options and future developments
    Tiedeman, Melissa
    Kim, E. Cynthia
    Flurie, Rachel
    Korch-Black, Karen
    Brandt, Nicole J.
    FORMULARY, 2011, 46 (07) : 268 - +
12345